What is Mindtension?
Mindtension operates at the intersection of medical technology and neuro-psychiatry, providing an ultra-precise, rapid diagnostic platform specifically engineered to measure ADHD. The current clinical paradigm for ADHD diagnosis is often characterized by subjective assessment, which frequently leads to suboptimal medication titration and patient distress. Mindtension mitigates these risks by introducing objective, data-driven metrics into the diagnostic workflow. By standardizing the identification process, the company aims to reduce the prevalence of overdosing and underdosing, thereby improving long-term patient outcomes and streamlining the path to effective therapeutic intervention.
How much funding has Mindtension raised?
Mindtension has raised a total of $2M across 1 funding round:
Angel/Seed
$2M
Angel/Seed (2023): $2M with participation from Israeli Innovation Authority, Galia Kut, and Arazim
Key Investors in Mindtension
Arazim
Arazim is a specialized firm focusing on data acquisition, sensors, and wireless systems, with a strong track record of supporting medical instrumentation and digital health innovation.
Israeli Innovation Authority
A government-backed agency dedicated to fostering technological innovation and supporting high-growth startups within the Israeli ecosystem.
Galia Kut
An individual investor providing strategic capital and support to early-stage ventures within the healthcare and diagnostic technology sectors.
What's next for Mindtension?
With this major strategic investment, Mindtension is poised to transition from its initial development phase into a broader commercialization strategy. The company will likely focus on expanding its clinical trial footprint and securing regulatory milestones necessary for widespread adoption in healthcare systems. As the demand for precision medicine in mental health continues to rise, Mindtension's ability to integrate its diagnostic tools into existing clinical infrastructure will be a key determinant of its long-term market penetration. Future growth will likely center on scaling its technical architecture and forging partnerships with pharmaceutical and clinical providers to standardize ADHD care protocols.
See full Mindtension company page
